Phibro Animal Health Corporatio (PAHC) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Analyst target reached at $53.38 — A.R:R is negative (-1.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: antibacterials and other related products.
Phibro Animal Health markets approximately 800 animal health and mineral nutrition product lines in approximately 90 countries across three segments: Animal Health ($963M, 74% of FY2025 net sales), Mineral Nutrition ($253M), and Performance Products ($80M). Revenue comes from... Read more
Sell if holding. Analyst target reached at $53.38 — A.R:R is negative (-1.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: antibacterials and other related products. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.6/10, moderate confidence.
Passes 3/6 gates (clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductantibacterials and other related products10-K Item 1A: 'a material portion of our sales and gross profits are generated by antibacterials and other related products'
- MEDIUMGeographicIsraeli and Brazilian operations10-K Item 1A: 'our dependence on our Israeli and Brazilian operations'
Material Events(8-K, last 90d)
- 2026-04-14Item 5.02LOWDirector Joyce J. Lee resigned from the Board effective April 15, 2026. Resignation was not due to any disagreement with the Company. No successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $53.38 — A.R:R is negative (-1.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: antibacterials and other related products. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $49.65. Score 5.6/10, moderate confidence.
Take-profit target: $58.88 (+10.3% upside). Prior stop was $49.65. Stop-loss: $49.65.
Concentration risk — Product: antibacterials and other related products; Analyst target reached - limited upside remaining; Leverage penalty (D/E 2.3): -1.5.
Phibro Animal Health Corporatio trades at a P/E of 23.2 (forward 15.5). TrendMatrix value score: 6.7/10. Verdict: Sell.
9 analysts cover PAHC with a consensus score of 2.4/5. Average price target: $51.
What does Phibro Animal Health Corporatio do?Phibro Animal Health markets approximately 800 animal health and mineral nutrition product lines in approximately 90...
Phibro Animal Health markets approximately 800 animal health and mineral nutrition product lines in approximately 90 countries across three segments: Animal Health ($963M, 74% of FY2025 net sales), Mineral Nutrition ($253M), and Performance Products ($80M). Revenue comes from antibacterials, anticoccidials, nutritional specialties, and vaccines sold to livestock producers and veterinarians. The U.S. accounted for 57% of FY2025 net sales.